World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
15191
World Ranking
3848
National Ranking
1764

Donald N. Forthal publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Donald N. Forthal sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 167 publications — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Donald N. Forthal D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Donald N. Forthal sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 54 D-Index — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Donald N. Forthal is affiliated with the University of California, Irvine in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with significant contributions to subfields such as Infectious Diseases, Immunology, Neurology, Virology, and Obstetrics and Gynecology.

The main topics covered in their work include COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Long-Term Effects of COVID-19, HIV Research and Treatment, COVID-19 Impact on Reproduction, Immune Cell Function and Interaction, and COVID-19 and Mental Health.

Recent notable publications by Donald N. Forthal include:

  • Prevention and Treatment of Monkeypox (2022) published in Drugs
  • Pharmaco-Immunomodulatory Therapy in COVID-19 (2020) published in Drugs
  • Early Outpatient Treatment for Covid-19 with Convalescent Plasma (2022) published in New England Journal of Medicine
  • Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic (2020) published in Drug Discovery Today
  • Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study (2023) published in The Lancet Microbe

Frequent co-authors collaborating with Donald N. Forthal include:

  • David Sullivan
  • Kelly A. Gebo
  • Evan M. Bloch
  • Giselle Mosnaim
  • Yuriko Fukuta

Forthal's work has been published extensively in journals such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Drugs
  • mBio
  • Transfusion
  • Advanced Drug Delivery Reviews

Best Publications

  • Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

    Neil M Flynn;Donald N Forthal;Clayton D Harro;Franklyn N Judson

  • Fc receptor but not complement binding is important in antibody protection against HIV

    Ann J. Hessell;Lars Hangartner;Meredith Hunter;Carin E. G. Havenith

  • Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

    Georgia D. Tomaras;Nicole L. Yates;Pinghuang Liu;Li Qin

  • The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.

    Haubrich Rh;Little Sj;Currier Js;Forthal Dn

  • Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

    Ann J. Hessell;Eva G. Rakasz;Pascal Poignard;Pascal Poignard;Lars Hangartner;Lars Hangartner

  • Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys

    Jinyan Liu;Kara L. O’Brien;Diana M. Lynch;Nathaniel L. Simmons

  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

    Dan H. Barouch;Dan H. Barouch;Jinyan Liu;Hualin Li;Lori F. Maxfield

  • Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

    Ann J. Hessell;Eva G. Rakasz;David M. Tehrani;Michael Huber

  • Early Outpatient Treatment for Covid-19 with Convalescent Plasma

    Unknown

  • Prophylaxis against Disseminated Mycobacterium avium Complex with Weekly Azithromycin, Daily Rifabutin, or Both

    Diane V. Havlir;Michael P. Dubé;Fred R. Sattler;Donald N. Forthal

  • Functions of Antibodies

    Donald N. Forthal

  • Pharmaco-Immunomodulatory Therapy in COVID-19.

    John G. Rizk;Kamyar Kalantar-Zadeh;Mandeep R. Mehra;Carl J. Lavie

  • Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells

    Donald N. Forthal;Gary Landucci;Eric S. Daar

  • Fluconazole Combined with Flucytosine for Treatment of Cryptococcal Meningitis in Patients with AIDS

    Larsen Ra;Bozzette Sa;Jones Be;Haghighat D

  • Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.

    Donald N. Forthal;Peter B. Gilbert;Gary Landucci;Tran Phan

  • Adjuvant-dependent Innate and Adaptive Immune Signatures of Risk of SIVmac251 Acquisition

    Monica Vaccari;Shari N Gordon;Slim Fourati;Luca Schifanella;Luca Schifanella

  • The Prevalence of Infection with Human Immunodeficiency Virus over a 10-Year Period in Rural Zaire

    N. Nzilambi;K. M. De Cock;D. N. Forthal;H. Francis

  • Fc receptor-mediated antiviral antibodies.

    Donald N Forthal;Christiane Moog

  • Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

    Cherie T Ng;J Pablo Jaworski;Pushpa Jayaraman;Pushpa Jayaraman;Pushpa Jayaraman;William F Sutton

  • Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

    Donald N. Forthal;Johannes S. Gach;Gary Landucci;Jakub Jez

  • A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

    Brian Moldt;Mami Shibata-Koyama;Eva G. Rakasz;Niccole Schultz

Frequent Co-Authors

David C. Montefiori
David C. Montefiori Duke University
Georgia D. Tomaras
Georgia D. Tomaras Duke University
Guido Ferrari
Guido Ferrari Duke University
Dennis R. Burton
Dennis R. Burton Scripps Research Institute
David Venzon
David Venzon National Institutes of Health
Mario Roederer
Mario Roederer National Institute of Allergy and Infectious Diseases
Marjorie Robert-Guroff
Marjorie Robert-Guroff National Institutes of Health
Genoveffa Franchini
Genoveffa Franchini National Institutes of Health
Nancy L. Haigwood
Nancy L. Haigwood Oregon Health & Science University
Susan W. Barnett
Susan W. Barnett Bill & Melinda Gates Foundation

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related online degrees can open doors in healthcare and research. Nursing professionals, for example, can explore specialized programs such as accelerated NP programs to quickly advance their clinical skills and expertise.

Transitioning within nursing roles is also common. Nurses seeking to evolve from family practice to acute care settings might find guidance in pathways like fnp to acute care np transitions, which outline the necessary steps and education adjustments.

For newcomers to nursing, enrolling in online ADN programs for non nurses provides a flexible route to gain foundational knowledge and credentials, preparing them for further specialization including immunological studies.

Moreover, understanding financial prospects is crucial. Nurses and healthcare professionals considering Immunology-related careers should review state-wise earning potentials, such as dnp salary by state, to make informed decisions about their educational investments and career moves.

Best Scientists Citing Donald N. Forthal

Trending Scientists

Recently Published Articles